Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Portfolio Pulse from Vandana Singh
Valneva SE reported that 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, 97% of participants retained neutralizing antibodies. The vaccine was FDA approved in November 2023. The data supports long-term durability and supplements existing FDA approval and ongoing regulatory processes. No safety concerns were identified, and EMA and Health Canada are reviewing marketing applications. Valneva's stock (VALN) is down 3.69% at $11.08.
December 04, 2023 | 2:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Valneva's chikungunya vaccine demonstrates long-term antibody response, with FDA approval already in place and further regulatory reviews pending. Stock price has decreased by 3.69%.
The positive long-term data for Valneva's vaccine could be a strong indicator of the product's efficacy and potential market success. However, the stock price has decreased, which may be due to market conditions or investor expectations not being met. The short-term impact is negative due to the current price action, but the long-term outlook could be positive if further regulatory approvals are granted.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100